How does raloxifene affect lipids and coronary heart disease (CHD)?
Raloxifene is associated with a decrease in total cholesterol and LDL. It does not have any effect on triglycerides, HDL, or coronary heart disease (CHD). Randomized trials of raloxifene’s use in postmenopausal women have consistently demonstrated a 10 percent to 15 percent reduction in serum low-density lipoprotein levels (1). This effect is similar in magnitude to the reduction seen with estrogen supplementation. Raloxifene has no apparent effect on total serum high-density lipoprotein levels or triglycerides. The RUTH (Raloxifene Use for The Heart) trial, specifically designed to assess the effect of raloxifene on coronary events, did not show any difference in coronary events between women taking placebo and those on raloxifene (2). This randomized trial included greater than 10,000 postmenopausal women with CHD or multiple risk factors for CHD who were followed for 5-6 years. Tamoxifen has similar lipid effects and data from the Study of Tamoxifen and Raloxifene (STAR) P-2 trial d
Related Questions
- In DCCT MS5exprt, FSCORE00 is Framingham risk score for coronary heart disease (chd; see Anderson et al., 1991: PMID: 1999037). How is it scored?
- Are elevated lipid levels associated with an increased risk for coronary heart disease (CHD)?
- How does raloxifene affect lipids and coronary heart disease (CHD)?
